Acadia Pharmaceuticals
ACAD
223 hedge funds and large institutions have $2.49B invested in Acadia Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 80 increasing their positions, 67 reducing their positions, and 46 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
52% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $7.41M
19% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 67
17% more capital invested
Capital invested by funds: $2.13B → $2.49B (+$367M)
0.7% more ownership
Funds ownership: 93.46% → 94.17% (+0.7%)
9% less funds holding
Funds holding: 246 → 223 (-23)
50% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$17.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.4M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$13.9M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$12.1M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$24.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.4M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$10.1M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.16M |
| 5 |
RI
RTW Investments
New York
|
-$8.96M |
ACAD Hedge Fund Activity: Q3 2022 in Review
223 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2022, worth a combined $2.49B — up 17% from $2.13B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of ACAD and 23 opened new positions — a net loss of 23 holders — while 67 trimmed existing stakes and 80 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $17.6M. The largest seller was Deep Track Capital, exiting entirely with an estimated $24.4M sold.
- 223 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2022, down from 246 in Q2 2022.
- Funds reported $2.49B of Acadia Pharmaceuticals stock for Q3 2022, up 17% quarter-over-quarter.
- 23 funds opened new Acadia Pharmaceuticals positions in Q3 2022 and 46 closed out, a net change of -23 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2022 was Jacobs Levy Equity Management, an estimated $17.6M added.
- The largest Acadia Pharmaceuticals seller in Q3 2022 was Deep Track Capital, an estimated $24.4M sold.
Based on aggregated 13F filings for Q3 2022.